Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05874921 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05874921 · ClinicalTrials.gov record · last posted 2025-02-28

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Study acronym: uTRACT
StatusRecruiting
PhaseNot specified
Started2023-11-17
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 28, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2023-05-22; most recent amendment 2025-02-25. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-11-28
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05874921
Lead Sponsor UroGen Pharma Ltd.
Conditions Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Enrollment 400 participants
Start Date 2023-11-17
Primary Completion 2026-04 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-28